pd 153035 has been researched along with erlotinib in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (6.67) | 29.6817 |
2010's | 14 (93.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
Gangjee, A; Ihnat, MA; Kurup, S; Shenoy, SS; Thorpe, JE | 1 |
Disch, BC; Gangjee, A; Ihnat, MA; Raghavan, S; Zhao, Y | 1 |
Disch, B; Gangjee, A; Ihnat, MA; Kurup, S; Thorpe, JE | 1 |
Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Kisliuk, RL; Thorpe, JE; Zhao, Y | 1 |
Du, QR; Fang, F; Gong, HB; Li, DD; Li, JR; Sun, J; Zhu, HL | 1 |
Bailey-Downs, LC; Gangjee, A; Ihnat, MA; Namjoshi, OA; Thorpe, JE; Yu, J | 1 |
Bastian, A; Disch, BC; Gangjee, A; Ihnat, MA; Raghavan, S; Thorpe, JE; Zaware, N | 1 |
Abou El Ella, DA; Aly, RM; El-Motwally, AM; Ibrahim, DA | 1 |
Hu, L; Li, Z; Liu, P; Pan, Z; Qin, X; Yang, L; Zeng, C | 1 |
Guo, Y; He, J; Li, Y; Liu, M; Liu, Y; Xiao, J; Yu, W; Zhang, Q | 1 |
Das, D; Hong, J | 1 |
Asquith, CRM; Drewry, DH; East, MP; Havener, TM; Johnson, GL; Laitinen, T; Morris, DC; Naegeli, KM; Wells, CI; Zuercher, WJ | 1 |
Asquith, CRM; Treiber, DK; Zuercher, WJ | 1 |
Asquith, CRM; Crona, DJ; Fleck, N; Grundner, C; Torrice, CD; Zuercher, WJ | 1 |
2 review(s) available for pd 153035 and erlotinib
Article | Year |
---|---|
The association between anti-tumor potency and structure-activity of protein-kinases inhibitors based on quinazoline molecular skeleton.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Humans; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines | 2019 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
13 other study(ies) available for pd 153035 and erlotinib
Article | Year |
---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Diamines; Indoles; Male; Melanoma; Mice; Mice, Nude; Molecular Structure; Phosphorylation; Pyrimidines; Pyrimidinones; Pyrroles; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Design, synthesis and evaluation of 2-amino-4-m-bromoanilino-6-arylmethyl-7H-pyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors and antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; ErbB Receptors; Humans; Models, Molecular; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor beta; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
N⁴-Aryl-6-substitutedphenylmethyl-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Diamines; Enzyme Activation; ErbB Receptors; Humans; Protein Kinase Inhibitors; Pyrimidines; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Novel tricyclic indeno[2,1-d]pyrimidines with dual antiangiogenic and cytotoxic activities as potent antitumor agents.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chick Embryo; Drug Screening Assays, Antitumor; Humans; Indenes; Melanoma, Experimental; Mice; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta | 2012 |
Discovery of 6-substituted 4-anilinoquinazolines with dioxygenated rings as novel EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Models, Molecular; Molecular Structure; Oxygen; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2012 |
N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastati
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Design; Humans; Melanoma, Experimental; Mice; Mice, Nude; Microwaves; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship | 2013 |
Synthesis and biological activity of 5-chloro-N⁴-substituted phenyl-9H-pyrimido[4,5-b]indole-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Cell Line, Tumor; Diamines; Halogenation; Humans; Indoles; Pyrimidines; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Molecular design and synthesis of certain new quinoline derivatives having potential anticancer activity.
Topics: Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; MCF-7 Cells; Molecular Structure; Protein Kinase Inhibitors; Quinolines; Structure-Activity Relationship | 2015 |
Discovery of new [1,4]dioxino[2,3-f]quinazoline-based inhibitors of EGFR including the T790M/L858R mutant.
Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Drug Discovery; ErbB Receptors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Molecular Structure; Mutation; Protein Binding; Quinazolines | 2016 |
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chordoma; Drug Design; ErbB Receptors; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines | 2019 |
Utilizing comprehensive and mini-kinome panels to optimize the selectivity of quinoline inhibitors for cyclin G associated kinase (GAK).
Topics: Cyclin G; Humans; Protein Kinase Inhibitors; Quinolines | 2019 |
Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.
Topics: Aniline Compounds; Antitubercular Agents; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Quinazolines; Quinolines; Structure-Activity Relationship | 2019 |